A Phase II Study of High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Graft-versus-host Disease (gvhd)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Karnofsky score = 70% 2) No evidence of progressive bacterial, viral, or fungal infection 3) Creatinine clearance > 50 mL/min/1.72m2 4) Total bilirubin, ALT and AST < 2 x the upper limit of normal (except for Gilbert’s syndrome) 5) Alkaline phosphatase = 250 IU/L 6) Left Ventricular Ejection Fraction (LVEF) > 45%

You may not be eligible for this study if the following are true:

  • 1) Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix E), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant. 2) Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy. 3) Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.